What are the recommended inhaler brands and generic names for each level of asthma severity?

Recommended Inhalers by Asthma Severity Level

For mild persistent asthma, use low-dose inhaled corticosteroids (ICS) such as fluticasone, budesonide, or mometasone as first-line controller therapy, with albuterol as rescue medication; for moderate persistent asthma, combine low-to-medium dose ICS with a long-acting beta-agonist (LABA) such as salmeterol or formoterol; and for severe persistent asthma, use high-dose ICS plus LABA combinations, with consideration of adding omalizumab for allergic asthma in patients ≥12 years. 1

Mild Intermittent Asthma (Step 1)

• No daily controller medication required 1
• Rescue/reliever therapy: Short-acting beta-agonist (SABA) as needed 1
  • Generic names: Albuterol, levalbuterol, pirbuterol 1
  • Dosing: Use as needed for symptoms, not to exceed 2 days per week (excluding exercise-induced symptoms) 1

Critical pitfall: If SABA use exceeds 2 days per week, this indicates inadequate control and requires stepping up to daily controller therapy 1, 2

Mild Persistent Asthma (Step 2)

Preferred Option for Ages 12+:

• Daily low-dose ICS as controller therapy 1
  • Generic names: Fluticasone propionate, budesonide, mometasone, beclomethasone, ciclesonide 1
  • Administration: Inhaled once or twice daily 1

Alternative Emerging Option (Ages 12+):

• As-needed ICS-formoterol combination (budesonide-formoterol) used concomitantly as both controller and reliever 1, 2
• This represents a paradigm shift allowing flexible dosing driven by symptoms 3, 4

Alternative Options (Less Preferred):

• Leukotriene modifiers: Montelukast (oral, once daily) or zileuton (oral, twice daily) 1
• Cromolyn or nedocromil (inhaled 4 times daily) 1

Rescue Therapy:

• SABA as needed (albuterol, levalbuterol) 1
• Newer option: Albuterol-budesonide fixed-dose combination as rescue medication reduces exacerbations by 26% compared to albuterol alone 5, 4

Moderate Persistent Asthma (Step 3)

Preferred Option (Ages 5+):

• Low-to-medium dose ICS plus LABA 1
  • ICS options: Fluticasone, budesonide, mometasone 1
  • LABA options: Salmeterol or formoterol 1, 6
  • Available combinations: Fluticasone/salmeterol (Advair), budesonide/formoterol (Symbicort) 1
  • Administration: Inhaled twice daily 1

Critical safety warning: LABAs must NEVER be used as monotherapy—they carry an FDA black-box warning and must always be combined with ICS due to increased risk of severe exacerbations and death when used alone 1, 6

Alternative Option:

• Medium-dose ICS alone (without LABA) 1
• This option should be given equal weight to adding LABA, particularly if concerns about LABA safety exist 1

For Ages 12+ (Alternative Approach):

• ICS-formoterol as maintenance and reliever therapy (MART): Single inhaler used as both daily controller and as-needed reliever 1, 2
• This approach is conditionally recommended and reduces exacerbations compared to higher-dose ICS-LABA with separate SABA reliever 1

Rescue Therapy:

• SABA as needed (albuterol) 1
• Or albuterol-budesonide combination for enhanced anti-inflammatory effect during symptom worsening 5, 4

Severe Persistent Asthma (Steps 5-6)

Preferred Regimen:

• High-dose ICS plus LABA 1
  • Combinations: Fluticasone/salmeterol 500/50 mcg or budesonide/formoterol at highest doses 1, 7
  • Administration: Twice daily 1

Additional Controller Options to Add:

• Long-acting muscarinic antagonist (LAMA): Tiotropium can be added to ICS-LABA for uncontrolled persistent asthma 1, 2
• Anti-IgE therapy: Omalizumab (subcutaneous injection every 2-4 weeks) for patients ≥12 years with allergic asthma (elevated IgE, positive skin testing or RAST) 1

For Ages 12+ (Preferred Alternative):

• ICS-formoterol as maintenance and reliever therapy is conditionally recommended over higher-dose ICS-LABA with separate SABA, showing superior outcomes in moderate-to-severe asthma 1, 2

Rescue Therapy:

• SABA as needed 1
• Albuterol-budesonide combination significantly reduces severe exacerbations in uncontrolled moderate-to-severe asthma 5, 4

Exacerbation Management:

• Oral systemic corticosteroids: Methylprednisolone, prednisolone, or prednisone for moderate-to-severe exacerbations 1
• Nebulized SABA plus ipratropium for severe exacerbations 1

Key Algorithmic Considerations

When stepping up therapy:

1. At Step 3, choose between medium-dose ICS alone OR low-dose ICS plus LABA—both options have equal weight 1
2. For patients ≥12 years, consider ICS-formoterol MART as it provides both maintenance and reliever in one inhaler 1, 2
3. If LABA is not used at Step 3+, adding LAMA (tiotropium) to ICS is recommended for uncontrolled asthma 1, 2

Common pitfalls to avoid:

• Never prescribe LABA without ICS—this is associated with increased mortality 1, 6
• SABA use >2 days/week indicates inadequate control requiring therapy escalation 1, 2
• LABAs (salmeterol, formoterol) are for long-term control, not acute symptom relief—patients must use SABA for acute symptoms 6
• Regular LABA use may lead to tolerance of bronchoprotective effects 6

Monitoring indicators for stepping up:

• Rescue inhaler use >2 days/week 1, 2
• Nighttime awakenings >2 nights/month 1
• Any limitation of normal activity 1
• Peak flow <80% of personal best 1